SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31: 7139.
  • 2
    Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 40815.
  • 3
    Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus [review]. Arthritis Rheum 2007; 56: 138496.
  • 4
    Berenson GS, Wattigney WA, Tracy RE, Newman WP III, Srinivasan SR, Webber LS, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992; 70: 8518.
  • 5
    Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000; 43: 14059.
  • 6
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399406.
  • 7
    Jimenez S, Garcia-Criado MA, Tassies D, Reverter JC, Cervera R, Gilabert MR, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44: 75661.
  • 8
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 9
    Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 5139.
  • 10
    Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 34129.
  • 11
    Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 23317.
  • 12
    Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000; 101: E1622.
  • 13
    Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 3317.
  • 14
    Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116: 6648.
  • 15
    Sass C, Herbeth B, Chapet O, Siest G, Visvikis S, Zannad F. Intima-media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort: effect of age, sex, anthropometry and blood pressure. J Hypertens 1998; 16: 1593602.
  • 16
    Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1519.
  • 17
    Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 45967.
  • 18
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 19
    Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142 (12 Pt 1): 95362.
  • 20
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 21
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 25963.
  • 22
    Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative centrifuge. Clin Chem 1972; 18: 499502.
  • 23
    Bots ML, Evans GW, Riley W, Meijer R, McBride KH, Paskett ED, et al. The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. Control Clin Trials 2003; 24: 75275.
  • 24
    Crouse JR III, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis: the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004; 18: 2318.
  • 25
    Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007; 23: 88594.
  • 26
    Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006; 27: 74655.
  • 27
    Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 134453.
  • 28
    Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 162030.
  • 29
    Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370: 15360.
  • 30
    Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 82936.
  • 31
    SAS/STAT user's guide. Cary (NC): SAS Institute; 1999.
  • 32
    Palatini P, Mormino P, Dorigatti F, Santonastaso M, Mos L, De Toni R, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006; 70: 57884.
  • 33
    Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 10717.
  • 34
    Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 2549.
  • 35
    Tyrrell PN, Beyene J, Benseler SM, Sarkissian T, Silverman ED. Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol 2007; 34: 21129.
  • 36
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 168595.
  • 37
    Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 11741.
  • 38
    Marcen R, Chahin J, Alarcon A, Bravo J. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transplant Proc 2006; 38: 242730.
  • 39
    Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case–control study. Arthritis Rheum 2006; 55: 8929.
  • 40
    Weigel G, Griesmacher A, DeAbreu RA, Wolner E, Mueller MM. Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. Thromb Res 1999; 94: 8794.
  • 41
    Stet EH, De Abreu RA, Bokkerink JP, Blom HJ, Lambooy LH, Vogels-Mentink TM, et al. Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts. Biochem J 1994; 304 (Pt 1): 1638.
  • 42
    Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 394757.
  • 43
    Cottiero RA, Madaio MP, Levey AS. Glomerular filtration rate and urinary albumin excretion rate in systemic lupus erythematosus. Nephron 1995; 169: 1406.
  • 44
    Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003; 34: 298594.
  • 45
    Taylor A, Shaw LJ, Fayad Z, O'Leary D, Brown BG, Nissen S, et al. Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis 2005; 180: 110.
  • 46
    Espeland MA, Evans GW, Wagenknecht LE, O'Leary DH, Zaccaro DJ, Crouse JR, et al. Site-specific progression of carotid artery intimal-medial thickness. Atherosclerosis 2003; 171: 13743.
  • 47
    Schott LL, Wildman RP, Brockwell S, Simkin-Silverman LR, Kuller LH, Sutton-Tyrrell K. Segment-specific effects of cardiovascular risk factors on carotid artery intima-medial thickness in women at midlife. Arterioscler Thromb Vasc Biol 2004; 24: 19516.
  • 48
    Espeland MA, Tang R, Terry JG, Davis DH, Mercuri M, Crouse JR III. Associations of risk factors with segment-specific intimal-medial thickness of the extracranial carotid artery. Stroke 1999; 30: 104755.
  • 49
    Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 2005; 16: 1494500.
  • 50
    Erzen B, Sabovic M, Sebestjen M, Kaplan-Pavlovcic S, Poredos P. Correlation between glomerular filtration and markers of the atherosclerotic process in young patients with myocardial infarction. Int J Cardiol 2007. E-pub ahead of print.
  • 51
    Szczepaniska Kostro J, Tolwinska J, Urban M, Gardziejczyk M, Glowinska B. Cardiac mass and function, carotid artery intima media thickness, homocysteine and lipoprotein levels in children and adolescents with growth hormone deficiency. J Pediatr Endocrinol Metab 2004; 17: 140513.
  • 52
    Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 188793.